Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.49 |
| ▸ | NPY1R | P25929 | 6/20 | 0.49 |
| ▸ | NPY2R | P49146 | 4/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | OTC | P00480 | 1/20 | 0.40 |
| ▸ | NRP1 | O14786 | 1/20 | 0.39 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7607432 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL31174187 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29358630 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL288599 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL10001721 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL31264971 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29947272 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL12533211 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30483977 | 0.97 | NPY4R (0.50) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29769333 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| US-7758771-B2 | Product for transformation of a toxic corrosive or environmentally-noxious liquid product into a non-corrosive or non-noxious residue | Meyer, Marie-Claude (FR) | 2010-07-20 | — | — | US | claimed |
| CN-100551518-C | Improved product for converting toxic corrosive or environmentally hazardous liquid products into non-corrosive or non-hazardous residues | MEYER MARIE CLAUDE (FR) | 2009-10-21 | — | — | CN | claimed |
| US-20090224202-A1 | PRODUCT FOR TRANSFORMATION OF A TOXIC CORROSIVE OR ENVIRONMENTALLY-NOXIOUS LIQUID PRODUCT INTO A NON-CORROSIVE OR NON-NOXIOUS RESIDUE | MEYER, MARIE-CLAUDE (FR) | 2009-09-10 | — | — | US | claimed |
| EP-1807188-B1 | IMPROVED PRODUCT FOR TRANSFORMATION OF A TOXIC CORROSIVE OR ENVIRONMENTALLY-NOXIOUS LIQUID PRODUCT INTO A NON-CORROSIVE OR NON-NOXIOUS RESIDUE | MEYER MARIE CLAUDE (FR) | 2009-08-12 | — | — | EP | claimed |
| CN-101065184-A | Improved product for converting toxic corrosive or environmentally hazardous liquid products into non-corrosive or non-hazardous residues | MEYER MARIE CLAUDE (FR) | 2007-10-31 | — | — | CN | claimed |
| EP-1807188-A2 | IMPROVED PRODUCT FOR TRANSFORMATION OF A TOXIC CORROSIVE OR ENVIRONMENTALLY-NOXIOUS LIQUID PRODUCT INTO A NON-CORROSIVE OR NON-NOXIOUS RESIDUE | Meyer, Marie-Claude (FR) | 2007-07-18 | — | — | EP | claimed |
| WO-2006048521-A2 | IMPROVED PRODUCT FOR TRANSFORMATION OF A TOXIC CORROSIVE OR ENVIRONMENTALLY-NOXIOUS LIQUID PRODUCT INTO A NON-CORROSIVE OR NON-NOXIOUS RESIDUE | MEYER MARIE-CLAUDE (FR) | 2006-05-11 | — | — | WO | claimed |
| EP-0995492-B1 | Product able to transform a toxic, corrosive or environmentally harmful liquid product into a non-aggressive or harmless residue | MEYER MARIE-CLAUDE (FR) | 2003-05-28 | — | — | EP | claimed |
| US-20020128361-A1 | Product capable of transforming a toxic, corrosive or environmentally harmful liquid product into a harmless or non-aggressive residue | MARIE-CLAUDE MEYER | 2002-09-12 | — | — | US | claimed |
| US-6380130-B1 | TO BE APPLIED ON THE LIQUID TO BE TREATED, THE PRODUCT SWELLS AND SOLIDIFIES, SOLID RESIDUE IS DISPOSED | Meyer, Marie-Claude (FR) | 2002-04-30 | — | — | US | claimed |
| US-5571892-A | HAVING A C-TERMINUS; TREATMENT FOR AIDS | SEIKAGAKU KOGYO CO., LTD. (JP) | 1996-11-05 | — | — | US | claimed |
| JP-7330572-A | — | — | None | — | — | JP | disclosed |
| US-20220289660-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2022-09-15 | — | — | US | disclosed |
| US-11292758-B2 | Compounds and methods for delivery of prostacyclin analogs | UNITED THERAPEUTICS CORPORATION (US) | 2022-04-05 | — | — | US | disclosed |
| CN-87104988-A | New polypeptide | — | 1988-03-02 | — | — | CN | disclosed |
| EP-0254516-A2 | Novel Peptides | NOVO NORDISK A/S (DK) | 1988-01-27 | — | — | EP | disclosed |
| EP-0194864-A2 | Novel peptides | NOVO NORDISK A/S (DK) | 1986-09-17 | — | — | EP | disclosed |
| US-4327072-A | Tyrosylated proinsulin C-peptide derivatives | SHIONOGI & CO., LTD. (JP) | 1982-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289660-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | NPY4R 633/4885NPY1R 554/4885NPY2R 562/4885 |
| US-11292758-B2 | Compounds and methods for delivery of prostacyclin analogs | PTGIR, PTGIS, PGF | NPY4R 517/4885NPY1R 469/4885NPY2R 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.